Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a ...

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD.

Up to 12 months, psychological interventions showed preventive effects for major depressive disorder reducing symptom severity and incidence.

Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

A study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Older adults with major depression exhibit unique patterns of risky driving independent of antidepressant use, suggesting the need for targeted interventions to ensure safety.

Unlike major depressive disorder, seasonal affective disorder usually lasts anywhere from a couple of weeks to a few months.

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Legislation would fund psilocybin research and hyperbaric oxygen therapy for veterans dealing with PTSD and other maladies.